Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
10 01 2023
10 01 2023
Historique:
accepted:
12
09
2022
received:
19
05
2022
pubmed:
15
10
2022
medline:
7
1
2023
entrez:
14
10
2022
Statut:
ppublish
Résumé
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized that the mutational status of bone marrow dysplastic cells and leukemic blasts, analyzed at the onset of AML using integrated multidimensional flow cytometry (MFC) immunophenotyping and fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS), could reconstruct leukemogenesis. Dysplastic cells were detected by MFC in 285 of 348 (82%) newly diagnosed patients with AML. Presence of dysplasia according to MFC and World Health Organization criteria had no prognostic value in older adults. NGS of dysplastic cells and blasts isolated at diagnosis identified 3 evolutionary patterns: stable (n = 12 of 21), branching (n = 4 of 21), and clonal evolution (n = 5 of 21). In patients achieving complete response (CR), integrated MFC and FACS with NGS showed persistent measurable residual disease (MRD) in phenotypically normal cell types, as well as the acquisition of genetic traits associated with treatment resistance. Furthermore, whole-exome sequencing of dysplastic and leukemic cells at diagnosis and of MRD uncovered different clonal involvement in dysplastic myelo-erythropoiesis, leukemic transformation, and chemoresistance. Altogether, we showed that it is possible to reconstruct leukemogenesis in ∼80% of patients with newly diagnosed AML, using techniques other than single-cell multiomics.
Identifiants
pubmed: 36240453
pii: 486809
doi: 10.1182/bloodadvances.2022008141
pmc: PMC9811200
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-173Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Nat Commun. 2020 Oct 21;11(1):5327
pubmed: 33087716
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
Blood. 2010 May 6;115(18):3776-86
pubmed: 20203266
Cancer. 2021 Jun 15;127(12):2003-2014
pubmed: 33626197
Leukemia. 2012 Sep;26(9):1908-75
pubmed: 22552007
Leukemia. 2012 Sep;26(9):1986-2010
pubmed: 22948490
Blood Adv. 2021 Sep 14;5(17):3279-3289
pubmed: 34459887
Nature. 2020 Nov;587(7834):477-482
pubmed: 33116311
Blood. 2008 Mar 15;111(6):3173-82
pubmed: 18192505
Blood. 2021 Nov 4;138(18):1733-1739
pubmed: 34115096
Biol Blood Marrow Transplant. 2017 Jul;23(7):1064-1071
pubmed: 28315400
Mod Pathol. 2015 Jul;28(7):965-76
pubmed: 25975285
Blood. 2010 Oct 14;116(15):2742-51
pubmed: 20581309
Br J Haematol. 2021 Mar;192(6):1054-1063
pubmed: 33618432
Nat Med. 2019 Jan;25(1):103-110
pubmed: 30510255
Nat Rev Cancer. 2017 Jan;17(1):5-19
pubmed: 27834397
Leukemia. 2022 Mar;36(3):656-663
pubmed: 34615986
J Pers Med. 2021 Mar 11;11(3):
pubmed: 33799721
Nat Commun. 2021 Dec 13;12(1):7244
pubmed: 34903734
Blood. 2013 Oct 31;122(18):3169-77
pubmed: 24047651
Blood. 2012 Apr 5;119(14):3203-10
pubmed: 22323480
Nature. 2014 Feb 20;506(7488):328-33
pubmed: 24522528
Blood. 2016 Feb 18;127(7):893-7
pubmed: 26631115
Blood Adv. 2020 Mar 10;4(5):943-952
pubmed: 32150611